|

Combined Use of Bacteroides Fragilis and BCAAs on HBsAg Clearance

RECRUITINGSponsored by First Affiliated Hospital of Fujian Medical University
Actively Recruiting
SponsorFirst Affiliated Hospital of Fujian Medical University
Started2025-06-01
Est. completion2026-03-01
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07257562

Summary

The goal of this prospective observational study is to determine the effects of concomitant administration of Bacteroides fragilis and Branched-Chain Amino Acids on hepatitis B virus clearance. The primary question it aims to answer is whether this concomitant administration can promote HBV clearance. The study will observe the HBV clearance rate in chronic hepatitis B patients who receive Bacteroides fragilis and BCAA as a supplement to their routine antiviral therapy. For comparison, researchers will compare the clearance rate in this group to that observed in a control group of chronic hepatitis B patients receiving a standard antiviral regimen based on PegIFNα2b and nucleoside analogs.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

\- chronic hepatitis B patients

Exclusion Criteria:

* patients with malignancies
* patients with other liver diseases
* pregnancy patients

Conditions2

Chronic Hepatitis bLiver Disease

Browse More Trials

Liver Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.